Description
BRD7 acts both as coactivator and as corepressor. For example, it activates the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. In addition, it is required for TP53-mediated cell-cycle arrest in response to oncogene activation. BRD7 promotes acetylation of TP53 at Lys-382, and thereby promotes efficient recruitment of TP53 to target promoters, inhibiting cell cycle progression from G1 to S phase